Prostate cancer is the most common form of cancer in men. Fortunately, it can usually be treated successfully. However, occasionally, patients will go into relapse and the cancer will come back after surgery.
In Oncotarget, Dr. Andrew Hsieh identified two proteins linked to prostate cancer outcomes. These proteins were identiied as YB-1 and MTA1. It was discovered that patients with high levels of these proteins were much more likely to suffer from prostate cancer recurrence. The identification of these proteins in prostate cancer treatment could help allow oncologists to predict which patients will relapse after surgery.
I am very interested in oncology; therefore, I believe the discovery of these two proteins is very important. If oncologists are able to predict which patients will relapse, patient care will be optimized and the best treatment plan can be formulated. Roughly every 1 in 7 men will be diagnosed with prostate cancer during his lifetime. Because prostate cancer is fairly common, it is important that scientists research ways to optimize treatment plans to allow for the best care possible.
My Article
Related Article
No comments:
Post a Comment